Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Raw Materials (2019 - 2025)

Outset Medical (OM) has disclosed Raw Materials for 7 consecutive years, with $27.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials rose 5.76% to $27.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.2 million, a 5.76% increase, with the full-year FY2025 number at $27.2 million, up 5.76% from a year prior.
  • Raw Materials was $27.2 million for Q4 2025 at Outset Medical, up from $26.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $27.2 million in Q4 2025 to a low of $10.9 million in Q1 2021.
  • A 5-year average of $20.9 million and a median of $20.8 million in 2022 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: skyrocketed 150.93% in 2021, then fell 9.3% in 2023.
  • Outset Medical's Raw Materials stood at $18.1 million in 2021, then grew by 13.85% to $20.6 million in 2022, then fell by 9.3% to $18.7 million in 2023, then soared by 37.41% to $25.7 million in 2024, then grew by 5.76% to $27.2 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Raw Materials are $27.2 million (Q4 2025), $26.0 million (Q3 2025), and $26.8 million (Q2 2025).